Literature DB >> 16459226

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.

Giulia Gramignano1, Maria Rita Lusso, Clelia Madeddu, Elena Massa, Roberto Serpe, Laura Deiana, Giovanna Lamonica, Mariele Dessì, Carla Spiga, Giorgio Astara, Antonio Macciò, Giovanni Mantovani.   

Abstract

OBJECTIVE: Fatigue is a multidimensional symptom that is described in terms of perceived energy, mental capacity, and psychological status: it can impair daily functioning and lead to negative effects on quality of life. It is one of the most common side effects of chemotherapy and radiotherapy. In recent studies, l-carnitine (LC) supplementation has been demonstrated to be able to improve fatigue symptoms in patients with cancer.
METHODS: In the present study we tested the efficacy and safety of LC supplementation in a population of patients who had advanced cancer and developed fatigue, high blood levels of reactive oxygen species, or both. As outcome measures we evaluated fatigue and quality of life in relation to oxidative stress, nutritional status, and laboratory variables, mainly levels of reactive oxygen species, glutathione peroxidase, and proinflammatory cytokines. From March to July 2004, 12 patients who had advanced tumors (50% at stage IV) at different sites were enrolled (male-to-female ratio 2:10, mean age 60 y, range 42-73). Patients were only slightly anemic (hemoglobin 10.9 g/dL) and hemoglobin levels did not change after treatment. LC was administered orally at 6 g/d for 4 wk. All patients underwent antineoplastic treatment during LC supplementation.
RESULTS: Fatigue, as measured by the Multidimensional Fatigue Symptom Inventory-Short Form, decreased significantly, particularly for the General and Physical scales, and for quality of life in each subscale of quality of life in relation to oxidative stress. Nutritional variables (lean body mass and appetite) increased significantly after LC supplementation. Levels of reactive oxygen species decreased and glutathione peroxidase increased but not significantly. Proinflammatory cytokines did not change significantly.
CONCLUSION: Improvement of symptoms with respect to fatigue and quality of life in relation to oxidative stress may be explained mainly by an increase in lean body mass, which may be considered the most important nutritional or functional parameter in assessing the cachectic state of patients. In this view, fatigue with related symptoms can well be considered an important constituent of cancer-related anorexia cachexia syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459226     DOI: 10.1016/j.nut.2005.06.003

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  41 in total

Review 1.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

2.  Effect of L-carnitine Supplementation on Nutritional Status and Physical Performance Under Calorie Restriction.

Authors:  Swati Jain; Som Nath Singh
Journal:  Indian J Clin Biochem       Date:  2014-05-04

Review 3.  Systematic review of the multidimensional fatigue symptom inventory-short form.

Authors:  Kristine A Donovan; Kevin D Stein; Morgan Lee; Corinne R Leach; Onaedo Ilozumba; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-08-22       Impact factor: 3.603

4.  Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).

Authors:  Satoru Iwase; Takashi Kawaguchi; Daisuke Yotsumoto; Takako Doi; Kyuichiro Miyara; Hiroki Odagiri; Kaoru Kitamura; Keisuke Ariyoshi; Tempei Miyaji; Hiroto Ishiki; Kenichi Inoue; Chizuko Tsutsumi; Yoshiaki Sagara; Takuhiro Yamaguchi
Journal:  Support Care Cancer       Date:  2015-06-24       Impact factor: 3.603

5.  Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Roberto Serpe; Elena Massa; Mariele Dessì; Filomena Panzone; Paolo Contu
Journal:  Oncologist       Date:  2010-02-15

6.  Prevalence of anxiety and depression and their risk factors in Chinese cancer patients.

Authors:  Jin Sheng Hong; Jun Tian
Journal:  Support Care Cancer       Date:  2013-10-04       Impact factor: 3.603

7.  Lower carnitine plasma values from malnutrition cancer patients.

Authors:  Estela Iraci Rabito; Izabel Arruda Leme; Rafael Demenice; Guilherme Vannucchi Portari; Alceu Afonso Jordão; José Sebastião dos Santos; Júlio Sérgio Marchini
Journal:  J Gastrointest Cancer       Date:  2013-09

8.  Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation.

Authors:  Liza Makowski; Robert C Noland; Timothy R Koves; Weibing Xing; Olga R Ilkayeva; Michael J Muehlbauer; Robert D Stevens; Deborah M Muoio
Journal:  FASEB J       Date:  2008-10-22       Impact factor: 5.191

Review 9.  Nutritional Interventions for Treating Cancer-Related Fatigue: A Qualitative Review.

Authors:  Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone
Journal:  Nutr Cancer       Date:  2019-01-26       Impact factor: 2.900

Review 10.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.